RSQ-020 - Extended stability evaluation of dexrazoxane solutions: implications for prolonged clinical administration

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: RSQ-020
• By: WANG, Dong (Tianjin Cancer Hospital Airport Hospital, China)
• Co-author(s): Prof Dong Wang (Tianjin Cancer Hospital Airport Hospital, Tianjin, China)
  Prof LIfeng Han (Instrumental analysis & Research Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China)
  Mrs. Mengrong Li (Tianjin Cancer Hospital Airport Hospital, Tianjin, China)
  
• Abstract:

  Introduction:
  Dexrazoxane, a cardioprotective adjunct in oncology, is clinically employed to mitigate anthracycline-induced cardiotoxicity. Currently, five manufacturers have obtained regulatory approval for dexrazoxane injections in China. However, stringent usage window (≤4-hour, diluted in sodium lactate Ringer's solution or 0.9% NaCl)..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login